Sarcoma News and Research

RSS

Inhibition of SIRT1 protein may hold promise for treatment of metastatic Ewing sarcoma

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), led by Oscar Martínez Tirado participated in an international study which suggests inhibition of Sirtuin1 (SIRT1) protein as a future treatment option for metastatic Ewing sarcoma. The results of the study were published in the journal Cancer Research.

31 Jan 2015

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

Gem Pharmaceuticals announced today that the initial soft tissue sarcoma (STS) patients have been enrolled into the Company's Phase 2 clinical trial. This open-label study will assess the efficacy and safety of Gem's lead compound, GPX-150 (an investigational medication), in approximately 30 adults as first-line therapy for advanced or metastatic disease.

23 Jan 2015

MET amplified in NSCLC irrespective of type, genetic background

A third of non-small-cell lung cancers show low- to high-level amplification of the MET gene, according to a German study, with no significant difference in frequency across different types of cancer and genetic backgrounds.

20 Jan 2015

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%.

20 Jan 2015

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the United States Food and Drug Administration has removed the partial clinical hold on the Company's aldoxorubicin clinical trials.

20 Jan 2015

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

Moffitt Cancer Center researchers have discovered a mechanism that leads to resistance to targeted therapy in melanoma patients and are investigating strategies to counteract it. Targeted biological therapy can reduce toxicity and improve outcomes for many cancer patients, when compared to the adverse effects of standard chemotherapeutic drugs.

12 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial evaluating the safety and efficacy of aldoxorubicin for the treatment of Kaposi's Sarcoma (KS) in HIV-infected patients.

8 Jan 2015

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced positive interim results from its ongoing Phase 2 clinical trial with aldoxorubicin for the treatment of unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer.

6 Jan 2015

Research findings may lead to new treatment strategies for Ewing sarcoma

The genetic abnormality that drives the bone cancer Ewing sarcoma operates through two distinct processes - both activating genes that stimulate tumor growth and suppressing those that should keep cancer from developing. These findings by Massachusetts General Hospital investigators, published in the November issue of Cancer Cell, may lead to new therapies targeting these aberrant mechanisms.

18 Dec 2014

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

Overall survival in patients with metastatic lung cancer does not correlate with Kirsten rat sarcoma viral oncogene homologue mutation subtypes, US researchers report.

12 Dec 2014

UT Southwestern biophysicist named recipient of 2015 Edith and Peter O'Donnell Award in Science

The Academy of Medicine, Engineering and Science of Texas has selected Dr. Yuh Min Chook, Professor of Pharmacology and of Biophysics at UT Southwestern Medical Center, as the recipient of the 2015 Edith and Peter O'Donnell Award in Science.

10 Dec 2014

PD-1, PD-L1 differentially expressed in NSCLC

The expression of the immune checkpoint protein programmed death-1 receptor and its ligand varies according to tumour and patient characteristics in oncogene-addicted non-small-cell lung cancer, research indicates.

9 Dec 2014

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that the Company has received written notice from the United States Food and Drug Administration that its clinical trials for aldoxorubicin have been placed on partial clinical hold.

3 Dec 2014

Researchers find unusual role of lactate in metabolism of alveolar soft part sarcoma

Researchers from Huntsman Cancer Institute at the University of Utah discovered the unusual role of lactate in the metabolism of alveolar soft part sarcoma (ASPS), a rare, aggressive cancer that primarily affects adolescents and young adults. The study also confirmed that a fusion gene is the cancer-causing agent in this disease.

27 Nov 2014

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

PharmaMar announces that Janssen Research & Development, LLC has submitted a New Drug Application (NDA) for YONDELIS (trabectedin) to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma (STS), including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an anthracycline.

26 Nov 2014

University of Louisville receives $50,000 grant for childhood cancer research

The St. Baldrick's Foundation, a volunteer-driven and donor-centered charity dedicated to raising money for childhood cancer research, has awarded a one-year, $50,000 grant to the University of Louisville (UofL).

21 Nov 2014

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a primary focus on China, today reported financial results for the three and nine months ended September 30, 2014.

14 Nov 2014

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival.

13 Nov 2014

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended September 30, 2014, and also provided an overview of recent accomplishments by and upcoming milestones for its clinical development programs.

4 Nov 2014

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Newly-identified cancer cell fingerprints in the blood could one day help doctors diagnose a range of children's cancers faster and more accurately, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference next week.

3 Nov 2014

Sarcoma News and Research

Inhibition of SIRT1 protein may hold promise for treatment of metastatic Ewing sarcoma

Gem Pharmaceuticals enrolls initial soft tissue sarcoma patients in GPX-150 Phase 2 clinical trial

MET amplified in NSCLC irrespective of type, genetic background

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

FDA removes partial clinical hold on CytRx's aldoxorubicin clinical trials

Researchers find mechanism that leads to resistance to targeted therapy in melanoma patients

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for HIV-related Kaposi's Sarcoma

CytRx reports positive interim results from aldoxorubicin Phase 2 trial for treatment of GBM

Research findings may lead to new treatment strategies for Ewing sarcoma

Metastatic lung cancer outcomes independent of KRAS mutation subtypes

UT Southwestern biophysicist named recipient of 2015 Edith and Peter O'Donnell Award in Science

PD-1, PD-L1 differentially expressed in NSCLC

CytRx's clinical trials for aldoxorubicin placed on partial clinical hold

Researchers find unusual role of lactate in metabolism of alveolar soft part sarcoma

Janssen submits YONDELIS NDA for treatment of advanced soft tissue sarcoma

University of Louisville receives $50,000 grant for childhood cancer research

CASI Pharmaceuticals announces net loss of $21.5M in third quarter 2014

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

CytRx provides overview of clinical development programs, reports 2014 Q3 financial results

Newly-identified cancer cell fingerprints in the blood could help diagnose childhood cancer

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News